Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies

Clinical Cancer Research

Volumn 22, Issue 8, 2016, Pages 2000-2008

  Hu, Wenyue ^a   Sung, Tae ^a   Jessen, Bart A ^a   Thibault, Stephane ^a   Finkelstein, Martin B ^a   Khan, Nasir K ^a   Sacaan, Aida I ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CASPASE 3; CASPASE 7; CD34 ANTIGEN; DOXORUBICIN; FULVESTRANT; PACLITAXEL; PALBOCICLIB; ANTINEOPLASTIC AGENT; ESTRADIOL; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW DERIVED MONONUCLEAR CELL; BONE MARROW EXAMINATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CELL AGING; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA SYNTHESIS INHIBITION; DOG; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MCF 7 CELL LINE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; RAT; TOXICITY TESTING; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD CELL COUNT; BONE MARROW; BONE MARROW CELL; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; DRUG POTENTIATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; METABOLISM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOOD CELL COUNT; BONE MARROW; BONE MARROW CELLS; CELL AGING; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DOGS; DRUG SYNERGISM; ESTRADIOL; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MODELS, ANIMAL; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84966341122     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1421     Document Type: Article

References (23)

1. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005;30:630-41.
2. Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 2011;137:1409-18.
3. Blachly JS, Byrd JC. Emerging drug profile: cyclin-dependent kinase inhibitors. Leuk Lymphoma 2013;54:2133-43.
4. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998;16: 2986-99.
5. Jessen BA, Lee L, Koudriakova T, Haines M, Lundgren K, Price S, et al. Peripheral white blood cell toxicity induced by broad spectrum cyclindependent kinase inhibitors. J Appl Toxicol 2007;27:133-42.
6. Illanes O, Anderson S, Niesman M, Zwick L, Jessen BA. Retinal and peripheral nerve toxicity induced by the administration of a pan-cyclin dependent kinase (cdk) inhibitor in mice. Toxicol Pathol 2006;34: 243-8.
7. Ramiro-Ibanez F, Trajkovic D, Jessen BA. Gastric and pancreatic lesions in rats treated with a pan-CDK inhibitor. Toxicol Pathol 2005;33: 784-91.
8. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009;11:R77.
9. Rocca A, Farolfi A, Bravaccini S, Schirone A, Amadori D. Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer. Expert Opin Pharmacother 2014;15:407-20.
10. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptorpositive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomized phase 2 study. Lancet 2015;16:25-35.
11. Mintzer DM, Billet SN, Chmielewski L. Drug-induced hematologic syndromes. Adv Hematol 2009;2009:1-11.
12. Budinsky RA. Hematotoxicity: chemically induced toxicity of the blood. In: Williams PL, editor. Principles of Toxicology: environmental and industrial applications. Hoboken, NJ: Wiley; 2000. p. 87-109.
13. Turgeon ML. Clinical hematology: theory & procedures. Philadelphia: Wolters Kluwer press. 5th edition, 2011.
14. Sun W, Wang D. Population pharmacokinetic-pharmacodynamic modeling and simulation of neutropenia in patients with advanced cancer treated with palbociclib. Presented at: The American Conference on Pharmacometrics (ACoP), October 4-7, 2015, Crystal City, Virginia (Poster S-18).
15. Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998;273:9357-60.
16. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol 2011;192:547-56.
17. Wright WE, Shay JW. Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr OpinGenet Dev 2001;11:98-103.
18. Morrison SJ, Prowse KR, Ho P, Weissman IL. Telomerase activity in hematopoietic cells is associated with self-renewal potential. Immunity 1996;5:207-16.
19. Stein GH, Drullinger LF, Soulard A, Dulic V. Differential roles for cyclindependent kinase inhibitors p21 and p16 in themechanisms of senescence and differentiation in human fibroblasts.Mol Cell Biol 1999;19:2109-17.
20. Morisake H, Ando A, Nagata Y, Pereira-Smith O, Smith JR, Ikeda K, et al. Complex mechanisms underlying impaired activation of CDK4 and CDK2 in replicative senescence: roles of p16, p21, and cyclin D1. Exp Cell Res 1999;253:503-10.
21. Karimi-Busheri F, Rasouli-Nia A, Mackey JR, Weinfeld M. Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res 2010;12:R31.
22. Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM, et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011;20:620-34.
23. Vega-Stromberg T. Chemotherapy-induced secondary malignancies. J Infus Nurs 2003;26:353-61.